IBB ETF Holds Fewer Bets Than You Think

An ETF’s label tells you the category, but the real story is always in the portfolio’s actual shape.

The iShares Biotechnology ETF (IBB) holds 249 different stocks, but once you account for how the money is weighted, it behaves like about 35 equally weighted holdings. This fund is designed to mirror the investment performance of an index of U.S. biotechnology companies. But like any fund, its simple name hides a specific set of exposures that are worth a closer look.

How Concentrated Is The Portfolio?

While the fund spreads its assets across many companies, the weight is not distributed evenly. The fund’s ten largest holdings make up 44% of its total assets. This means a significant portion of the fund’s movement will be tied to the fortunes of a relatively small group of companies.

The concentration is apparent at the very top. The single largest holding is Vertex Pharmaceuticals, which alone accounts for 7.8% of the fund. It is followed closely by other major players like Amgen at 7.6% and Gilead Sciences at 7.0%. When just three companies command such a share, their performance can have a noticeable impact on the entire fund.

Where Is The Money Actually Invested?

Looking beneath the broad Health Care label, which accounts for 100% of the fund, reveals a further tilt. The portfolio is overwhelmingly dedicated to one specific sub-industry. Biotechnology is the largest industry in the fund at 87% of assets, making this a very direct play on that particular field.

The remainder is primarily in Life Sciences Tools & Services, the next largest industry at 9.2%. Together, these two areas represent the vast majority of what you own. Understanding a fund’s internal structure is a key part of assessing its potential, a topic that is relevant for many popular funds today.

Is This The Exposure You Intended?

A fund’s name gives you the category, but its composition gives you the reality. In the case of IBB, that reality is a portfolio with significant weight in its top positions and a deep focus on the Biotechnology sub-industry. This isn’t a judgment on whether that’s good or bad, but a simple statement of fact. The only question for an investor is whether this particular shape, a focused instrument rather than a broadly diversified one, is the one you thought you were buying.

Is There A Better Version Of This?

Seeing what is inside IBB is half the picture. The other half is whether you are getting that exposure at a fair price and a competitive return, or whether a similar fund delivers much the same holdings for less.

Our ETF Valuation and Performance Scorecard ranks the major funds side by side on valuation versus their own history, trailing and risk-adjusted return, volatility and expense ratio, so you can see whether IBB is a sensible way to own what it holds, and which comparable funds give you a similar basket on better terms.

The Fund Is Diversified. Is The Rest Of Your Portfolio?

A fund spreads risk by design, which makes it easy to overlook a single stock elsewhere in the portfolio that has grown too large. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.